Filing Details

Accession Number:
0001225208-23-005754
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-05-11 18:11:31
Reporting Period:
2023-05-07
Accepted Time:
2023-05-11 18:11:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1099800 Edwards Lifesciences Corp EW Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842) 364316614
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1204551 A Michael Mussallem One Edwards Way
Irvine CA 92614
Chairman & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-05-07 20,777 $0.00 81,725 No 4 M Direct
Common Stock Acquisiton 2023-05-10 29,375 $35.20 111,100 No 4 M Direct
Common Stock Disposition 2023-05-10 5,984 $88.94 105,116 No 4 S Direct
Common Stock Disposition 2023-05-10 9,500 $0.00 95,616 No 4 G Direct
Common Stock Disposition 2023-05-10 13,891 $88.29 81,725 No 4 S Direct
Common Stock Acquisiton 2023-05-10 9,500 $0.00 3,616,922 No 4 G Indirect By Living Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 G Direct
No 4 S Direct
No 4 G Indirect By Living Trust
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Performance Rights Disposition 2023-05-07 20,777 $0.00 20,777 $0.00
Common Stock Employee Stock Option (Right to Acquire) Disposition 2023-05-10 29,375 $0.00 29,375 $35.20
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
5,698 2023-05-07 2027-05-06 No 4 M Direct
0 2016-06-12 2023-05-11 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 371,690 Indirect 401(k)
Footnotes
  1. On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4.
  2. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022.
  3. This transaction was executed in multiple trades at prices ranging from $88.84 to $89.25 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
  4. This transaction was executed in multiple trades at prices ranging from $87.83 to $88.83 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.